"1 in 2 Biliary Tract Cancer Patients Become Eligible for Surgery After 'GemCisAbraxane' Therapy"
Bundang CHA Hospital research team announces study results
"Genomic and transcriptomic analyses conducted, confirming the potential for personalized treatment in biliary tract cancer"
Bundang CHA Hospital announced on February 9 that its multidisciplinary hepatobiliary-pancreatic cancer team has confirmed in a study of patients with advanced biliary tract cancer that survival outcomes with the combination therapy of gemcitabine, cisplatin, and nab-paclitaxel (GemCisAbraxane, hereafter GemCisAbraxane therapy) differ according to the patient’s molecular characteristics. The study results were published in the latest issue of the international journal Hepatology.
From left: Jeon Hongjae, Professor of Oncology at Bundang CHA Hospital; Hwang Sohyun, Professor of Pathology; Kim Chan, Professor of Oncology; Yang Seokjeong, Professor of Surgery; and Woo Seonjeong, Master's student, Department of Biomedical Sciences, CHA University.
View original imageThe research team conducted a prospective cohort study of 119 patients with advanced biliary tract cancer who received GemCisAbraxane therapy between July 2021 and December 2022. The analysis showed a median progression-free survival of 8.3 months and a median overall survival of 19.8 months. The treatment outcomes with GemCisAbraxane therapy reported in the previous phase 2 clinical trial were reproduced in real-world clinical practice.
In particular, among 37 patients with locally advanced biliary tract cancer who were initially considered inoperable, 18 became eligible for curative surgery after treatment due to tumor shrinkage. The conversion surgery rate was 48.6%.
GemCisAbraxane therapy has drawn attention as an alternative to the existing standard treatment of gemcitabine plus cisplatin. In a past phase 3 clinical trial, however, its efficacy could not be clearly demonstrated in the overall patient population because of toxicity issues related to nab-paclitaxel. The hospital explained that this study showed GemCisAbraxane therapy can become a clinically meaningful treatment option through dose adjustment and patient management strategies tailored to real-world clinical settings.
The research team obtained pre-treatment tumor tissue samples from 108 patients and performed both genomic analysis and RNA (ribonucleic acid) sequencing. Based on these data, biliary tract cancer was classified into four molecular subtypes: cholangiocyte-like, stroma-rich, metabolic, and inflammation/proliferation.
The analysis found that the therapeutic effect of GemCisAbraxane therapy was most favorable in the cholangiocyte-like subtype. In contrast, the inflammation/proliferation subtype was associated with TP53 mutations and an immunosuppressive tumor microenvironment, and therefore showed relatively poor prognosis. These findings indicate that the response to GemCisAbraxane therapy can vary depending on the biological characteristics of the tumor.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Jeon Hongjae, Professor at Bundang CHA Hospital who led the study, said, “GemCisAbraxane therapy not only demonstrated meaningful survival outcomes in a prospective cohort, but also provided evidence to explain differences in treatment response and prognosis according to molecular subtype,” adding, “These results will serve as foundational data for future precision treatment strategies and combination therapy clinical trial designs in biliary tract cancer.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.